Watch URGN. Know when insiders buy.
One email the day a filing lands. Free.
URGN
UroGen Pharma Ltd.
35.62
+0.61 +1.74%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
15
FLAG · insiders 25, shorts 5
Insiders, 90 days
−$3M
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -9.14%REV TTM $188.7M +100.3%NET INCOME −$97.6MNET DEBT $120.9M52W 17.00 – 50.29NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $72.5M | +199.2% | 90.9% | $111K | −$14.4M | — | -0.28 | −$33M | $60K | −$33.1M | Aug 5 |
| Q1 2026 · Mar 31 | $51M | +151.6% | 91.9% | −$20.3M | −$23.6M | — | -0.47 | −$45.3M | $54K | −$45.4M | May 6 |
| Q4 2025 · Dec 31derived | $37.8M | +54.0% | 91.3% | −$19.1M | −$26.4M | — | -0.53 | −$38.3M | $17K | −$38.3M | Mar 2 |
| Q3 2025 · Sep 30 | $27.5M | +9.0% | 88.1% | −$27.4M | −$33.3M | — | -0.69 | −$42.3M | $87K | −$42.4M | Nov 6 |
| Q2 2025 · Jun 30 | $24.2M | +10.8% | 85.3% | −$41.4M | −$49.9M | — | -1.05 | −$39.8M | $141K | −$40M | Aug 5 |
| Q1 2025 · Mar 31 | $20.3M | +7.8% | 88.5% | −$36.9M | −$43.8M | — | -0.92 | −$42M | $44K | −$42.1M | May 6 |
| Q4 2024 · Dec 31 | $24.6M | +4.4% | 89.9% | −$27.7M | −$37.5M | — | -0.80 | −$13.6M | $115K | −$13.7M | Mar 2 |
| Q3 2024 · Sep 30 | $25.2M | +20.9% | 90.3% | −$17.5M | −$23.7M | — | -0.51 | −$27.7M | $96K | −$27.8M | Nov 6 |
| Q2 2024 · Jun 30 | $21.8M | — | 89.8% | −$25.8M | −$33.4M | — | -0.82 | −$23.7M | $84K | −$23.8M | Aug 7 |
| Q1 2024 · Mar 31 | $18.8M | — | 90.8% | −$25.7M | −$32.3M | — | -0.87 | −$31.7M | $0 | −$31.7M | May 12 |
| Q4 2023 · Dec 31 | $23.5M | — | 90.3% | −$14.6M | −$26M | — | -0.72 | −$13M | $56K | −$13.1M | Mar 10 |
| Q3 2023 · Sep 30 | $20.9M | — | 88.6% | −$13.5M | −$21.9M | — | -0.68 | −$17.3M | $100K | −$17.4M | Mar 10 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $109.8M | 88.7% | −$124.9M | −$153.5M | -139.8% | -3.19 | −$162.4M | $289K | −$162.7M | — | — |
| FY2024 · to Dec 31 | $90.4M | 90.2% | −$96.8M | −$126.9M | -140.4% | -2.96 | −$96.8M | $295K | −$97.1M | — | — |
| FY2023 · to Dec 31 | $82.7M | 88.7% | −$65.5M | −$102.2M | -123.6% | -3.55 | −$76.4M | $194K | −$76.6M | — | — |
| FY2022 · to Dec 31 | $64.4M | 88.1% | −$79M | −$109.8M | -170.6% | -4.81 | −$87.6M | $254K | −$87.8M | — | — |
| FY2021 · to Dec 31 | $48M | 89.3% | −$92.3M | −$110.8M | -230.7% | -4.96 | −$84.9M | $752K | −$85.6M | — | — |
| FY2020 · to Dec 31 | $11.8M | 91.4% | −$126.7M | −$128.5M | -1088.9% | -5.90 | −$105.9M | $1.2M | −$107.1M | — | — |
Every number comes from UroGen Pharma Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.